BCL-9, one of the crucial counterparts of the nuclear component Legless (Lgs) in Wnt pathway, is highly expressed in human CRC tissues, and the BCL-9/β-catenin complex has been identified as a crucial target for cancer therapy [12]. Here, BCL9 is linked to colorectal carcinoma.